Interview with Paul A. Bunn, Jr., MD

Tom Dilling
University of Pennsylvania Cancer Center
Last Modified: May 20, 1996

Dr. Bunn: There are six new drugs which have been approved or are about to be approved for treating lung cancer and they're probably all six of them better than drugs which we've had in the past, and I think they will improve survival for patients with lung cancer.

I guess the second point is that the patients who have "earlier-stage" [lung cancer], if you give them chemotherapy with radiation or with surgery or all three together, it is providing better survival than what we had in the past with just surgery alone.

And the last thing you can tell your people is: Don't smoke!

OncoLink: Just to reiterate again for all our listeners and readers out there who were not at this talk....

Dr. Bunn: They're not here? I thought they were all here!

  • laugh
  • OncoLink: Yes, well....

    What were those six new drugs which you see as on the forefront?

    Dr. Bunn: There's two taxanes, paclitaxel and docetaxel, which some people call taxol and taxotere; there's two topoisomerase I inhibitors, irinotecan and topotecan; and then there's navelbine and gemcitabine (Gemzar®).

  • Keywords

    Click on any of these terms for more related articles


    Where Are the Adults in the Room?
    by Rodney Warner, JD
    November 20, 2015

    Related News

    CDC: E-Cigarette Use Highest Among 18- to 24-Year-Olds

    Nov 25, 2015

    Almost 4 percent of all adult Americans use them, new survey shows

    Folic Acid Enrichment May Reduce Specific Pediatric Cancers

    May 22, 2012

    Postfortification of grains, decrease seen in Wilms tumor, primitive neuroectodermal tumor incidence

    Progression-Free Survival Not Tied to R-CHOP Dose Density

    Sep 21, 2011

    No significant difference for patients with indolent B-cell lymphoma treated with R-CHOP-14 or -21